Webinar: T-cell engager development: the role of hCD3 models in safety and efficacy assessment

‍

Thursday, September 25, 2025 | Live Webinar

Title: "T-cell engager development: the role of hCD3 models in safety and efficacy assessment"‍

Presenter: Fabiane Sônego, Director – Preclinical Models & Services

Presentation highlights:

▶️ CD3xTAA bispecific antibodies induce anti-tumor response in both genO-hCD3ε and genO-panhCD3 mice

▶️ genO-hCD3ε and genO-panhCD3 mice are suitable for studies in an auto-immunity context

▶️ genO-pan-hCD3 mouse model can be used to assess T-cell engager-mediated cytokine release and associated clinical signs

‍

Cited scientific articles:

• genO-hCD3ε:
   
  • HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors, Mol Cancer Ther, 2024 (Harpoon Therapeutics)
   
  • A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies, Mol Cancer Ther, 2025 (Pfizer)
   
  • Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model, Sci Rep, 2022 (Bristol Myers Squibb)
 
• genO-panhCD3 model:
   
  • An affinity-modulated T-cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release, J Immunother Cancer, 2025 (AstraZeneca)
   
  • Bi-specific autoantigen-T-cell engagers as targeted immunotherapy for autoreactive B-cell depletion in autoimmune diseases, Front Immunol, 2024 (Mario Negri Istituto)
 
• genO-hFcRn model:
   
  • Generation of a double transgenic humanized neonatal Fc receptor (FcRn) / albumin mouse to study the pharmacokinetics of albumin-linked drugs, J Control Release, 2015 (Novozymes)
 
• genO-BRGSF-HIS model:
   
  • Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized genO-BRGSF-HIS preclinical model, Front Immunol, 2024 (genOway)
   
  • Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies, Front Immunol, 2025 (genOway)
   
  • NI-3201 is a bispecific anitbody mediating PD-L1-dependent CD28 co-stimulation on T cells for enhanced tumor control, Cancer Immunol Res, 2025 (Light Chain Bioscience)

‍